Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss.

Karthik Murugadoss^1,2, A J Venkatakrishnan^1,2, Christopher J Gregg¹, Venky Soundararajan^3,4

¹nference, Cambridge, MA, USA.

²Metabolism Agentic Intelligence Atlas (MAIA), Cambridge, MA, USA.

³nference, Cambridge, MA, USA. venky@nference.net.

⁴Metabolism Agentic Intelligence Atlas (MAIA), Cambridge, MA, USA. venky@nference.net.

PubMed PMC DOI PDF

Abstract

Semaglutide is often optimized to maximize weight loss, yet it remains unclear whether long-term cardiovascular benefit is more closely associated with achieved weight reduction or therapeutic exposure. We conducted a retrospective observational study using a federated, de-identified U.S. electronic health record network comprising 47,199 patients with pre-existing cardiovascular disease who initi…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.